Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review.

IF 2.6 4区 医学 Q2 UROLOGY & NEPHROLOGY Therapeutic Advances in Urology Pub Date : 2022-07-18 eCollection Date: 2022-01-01 DOI:10.1177/17562872221106883
Elizabeth E Ellis, Thomas P Frye
{"title":"Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review.","authors":"Elizabeth E Ellis,&nbsp;Thomas P Frye","doi":"10.1177/17562872221106883","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Our goal is to review current literature regarding the role of multi-parametric magnetic resonance imaging (mpMRI) in the active surveillance (AS) of prostate cancer (PCa) and identify trends in rate of reclassification of risk category, performance of fusion biopsy (FB) <i>versus</i> systematic biopsy (SB), and progression-free survival.</p><p><strong>Methods: </strong>We performed a comprehensive literature search in PubMed and identified 121 articles. A narrative summary was performed.</p><p><strong>Results: </strong>Thirty-two articles were chosen to be featured in this review. SB and FB are complementary in detecting higher-grade disease in follow-up. While FB was more likely than SB to detect clinically significant disease, FB missed 6.4-11% of clinically significant disease. Imaging factors that predicted upgrading include number of lesions on magnetic resonance imaging (MRI), lesion density, and MRI suspicion level.</p><p><strong>Conclusion: </strong>Incorporating mpMRI FB in conjunction with SB should be part of contemporary AS protocols. mpMRI should additionally be used routinely for follow-up; however, mpMRI is not currently sensitive enough in detecting disease progression to replace biopsy in the surveillance protocol.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/17/10.1177_17562872221106883.PMC9297445.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562872221106883","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Our goal is to review current literature regarding the role of multi-parametric magnetic resonance imaging (mpMRI) in the active surveillance (AS) of prostate cancer (PCa) and identify trends in rate of reclassification of risk category, performance of fusion biopsy (FB) versus systematic biopsy (SB), and progression-free survival.

Methods: We performed a comprehensive literature search in PubMed and identified 121 articles. A narrative summary was performed.

Results: Thirty-two articles were chosen to be featured in this review. SB and FB are complementary in detecting higher-grade disease in follow-up. While FB was more likely than SB to detect clinically significant disease, FB missed 6.4-11% of clinically significant disease. Imaging factors that predicted upgrading include number of lesions on magnetic resonance imaging (MRI), lesion density, and MRI suspicion level.

Conclusion: Incorporating mpMRI FB in conjunction with SB should be part of contemporary AS protocols. mpMRI should additionally be used routinely for follow-up; however, mpMRI is not currently sensitive enough in detecting disease progression to replace biopsy in the surveillance protocol.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多参数磁共振成像融合活检在前列腺癌主动监测中的作用:系统综述。
背景:我们的目的是回顾目前关于多参数磁共振成像(mpMRI)在前列腺癌(PCa)主动监测(AS)中的作用的文献,并确定风险类别重新分类率、融合活检(FB)与系统活检(SB)的表现以及无进展生存期的趋势。方法:我们在PubMed中进行了全面的文献检索,并确定了121篇文章。进行了叙述性总结。结果:32篇文章入选本综述。SB和FB在随访中发现高级别疾病方面是互补的。虽然FB比SB更容易发现临床重要疾病,但FB遗漏了6.4-11%的临床重要疾病。预测升级的影像学因素包括磁共振成像(MRI)病变数量、病变密度和MRI可疑程度。结论:将mpMRI FB与SB结合应成为当代AS治疗方案的一部分。此外,应常规使用mpMRI进行随访;然而,mpMRI目前在检测疾病进展方面还不够敏感,无法在监测方案中取代活检。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
39
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Urology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of urology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in urology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest across all areas of urology, including treatment of urological disorders, with a focus on emerging pharmacological therapies.
期刊最新文献
Clinical use of nadofaragene firadenovec-vncg Effect of surgical, medical, and behavioral weight loss on hormonal and sexual function in men: a contemporary narrative review Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK PARP inhibitors alone or in combination for prostate cancer. Comparison of ureteoroscopy and laser stone fragmentation between Holmium: YAG laser with MOSES versus non-MOSES technology: a prospective single-center propensity score-matched analysis using similar laser settings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1